Policy & Regulation
Innovent doses first patient with IBI188 under Phase I clinical trial in China
15 January 2019 -

Biopharmaceutical company Innovent Biologics Inc (HKEX:01801) reported on Monday that it has started treatment of the first patient under its phase I clinical trial of anti-CD47 monoclonal antibody (IBI188) for patients with advanced malignancies in China.

This phase I CIBI188A101 clinical study will evaluate the safety, tolerability and efficacy of IBI188 in the treatment of patients with advanced malignancies.

The CIBI188A101 study is a Phase I clinical study conducted in China to evaluate the safety, tolerability, and efficacy of IBI188 in the treatment of patients with advanced malignancies. The primary objectives are to evaluate the safety, tolerability and phase II recommended doses of IBI188 as a monotherapy and in combination with other agents in subjects with advanced malignancy. The phase 1a study explores the priming and maintenance dose of IBI188 as monotherapy.

IBI188, which is a fully human monoclonal antibody targeting CD47, can bind to the CD47 antigen on the surface of tumour cells, block the CD47-SIRPα signaling pathway, inhibit the "Don't Eat Me" signal and promote the phagocytosis of tumour cells by macrophages, thereby exerting an anti-tumour effect, added the company.

In conjunction, the company said it will launch several clinical trials to assess its safety and efficacy in multiple tumour types, including non-Hodgkin's lymphoma and ovarian cancer.

Login
Username:

Password: